Clinical Trial Detail

NCT ID NCT04219254
Title A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BioInvent International AB
Indications

melanoma

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

BI-1206 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.